{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:40:53Z","timestamp":1793317253320,"version":"4.5.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Modern Rheumatology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.3109\/s10165-008-0045-0","type":"journal-article","created":{"date-parts":[[2014,1,2]],"date-time":"2014-01-02T15:08:02Z","timestamp":1388675282000},"page":"252-262","source":"Crossref","is-referenced-by-count":129,"title":["Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study"],"prefix":"10.1093","volume":"18","author":[{"given":"Nobuyuki","family":"Miyasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The CHANGE Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,2]]},"reference":[{"issue":"1","key":"CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422010-00001","volume":"22","author":"Kvien TK","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"CIT0002","first-page":"4","volume":"15","author":"Miyasaka N","year":"2005","journal-title":"Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheuma-tol"},{"issue":"67","key":"CIT0003","first-page":"1","volume":"30","author":"Shiokawa Y","year":"2003","journal-title":"Rheumatic diseases at the dawn of the millennium. J Rheumatol"},{"issue":"67","key":"CIT0004","first-page":"47","volume":"30","author":"Mugitani M","year":"2003","journal-title":"Bone and joint diseases around the world. Japan: strategy for rheumatic disease control. J Rheumatol"},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1136\/ard.2004.033761","volume":"64","author":"Hakoda M","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"Elliott MJ","year":"1994","journal-title":"Lancet"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"Weinblatt ME","year":"2003","journal-title":"Arthritis Rheum"},{"key":"CIT0009","first-page":"37","volume":"33","author":"Abe T","year":"2006","journal-title":"J Rheumatol"},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/s10165-006-0532-0","volume":"17","author":"Yamanaka H","year":"2007","journal-title":"Mod Rheumatol"},{"key":"CIT0011","first-page":"63","volume":"16","author":"Miyasaka N","year":"2006","journal-title":"Guidelines for the proper use of etanercept in Japan. Mod Rheumatol"},{"key":"CIT0013","first-page":"2563","volume":"30","author":"Furst DE","year":"2003","journal-title":"J Rheumatol"},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"Van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, et al.","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"CIT0015","first-page":"437","volume":"16","author":"Kashiwazaki S","year":"1996","journal-title":"Jpn J Inflamm"},{"key":"CIT0016","first-page":"1932","volume":"354","author":"Maini R","year":"1999","journal-title":"ATTRACT Study Group. Lancet"},{"key":"CIT0017","first-page":"732","volume":"66","author":"Burmester GR","year":"2007","journal-title":"Adalimumab alone and in com-bination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the research in active rheumatoid arthritis (ReAct) trial. Ann Rheum Dis"},{"key":"CIT0018","first-page":"26","volume":"54","author":"Breedveld FC","year":"2006","journal-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combina-tion therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous meth-otrexate treatment. Arthritis Rheum"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"Schiff MH","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/s10165-008-0045-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:54:28Z","timestamp":1642560868000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/18\/3\/252-262\/6313842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":17,"aliases":["10.1007\/s10165-008-0045-0"],"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,1,2]]},"published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.3109\/s10165-008-0045-0"],"URL":"https:\/\/doi.org\/10.3109\/s10165-008-0045-0","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}